Animal testing

In common with all companies developing and marketing chemical substances, Johnson Matthey must comply with international legislation to make toxicity information available to assure product safety for humans, wildlife and the environment. We are committed to ethical principles of animal protection and our corporate approach is based on the following principles:

  1. Johnson Matthey has embraced the '3Rs' approach in relying on properly validated alternative methods which replace, refine or reduce the use of animal testing. Therefore, we now place emphasis firstly on applying the latest integrated testing strategies (e.g. in vitro assays, computer modelling of effects, read across and in vivo test-waiving approaches). New techniques are continually tracked and implemented into our strategies as they are endorsed by regulatory bodies, such as the OECD.
  2. If, after confirming that suitable data do not already exist, in vivo studies are unavoidable, we always seek to limit new testing and avoid duplication by undertaking work in collaboration with industrial partners with the same data needs.
  3. It is ensured that any studies comply with all applicable laws, regulations, licensing and welfare codes.
  4. Johnson Matthey only uses fully accredited contract research organisations and does not undertake any in house in vivo toxicity testing.
  5. As a fundamental operating principle, our oversight procedures require that our businesses do not commission vertebrate animal studies until a justification has been carefully considered and approved at group level.

The group does not manufacture any cosmetics or consumer goods and testing is therefore aligned to regulatory requirements for industrial chemicals. Any testing required as a result of registration requirements imposed under the REACH-like regulations is minimised by working within industry consortia.

Johnson Matthey shares current societal and political concern over animal testing and we only commission studies when mandated by law and if no alternatives exist.

We remain optimistic that advances in toxicology science and regulatory acceptance of new assessment methodologies will enable us to further reduce in vivo testing numbers while continuing to ensure our products are safe for humans and the environment.

View all policies, disclosures and position statements